Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Príomhchruthaitheoirí: V. I. Ignatyeva (Údar), S. V. Moiseev (Údar), N. M. Bulanov (Údar), E. A. Karovajkina (Údar), A S. Moiseev (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: IRBIS LLC, 2019-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...